Hepatocellular carcinoma (HCC) remains among the neoplastic diseases with the most unfavorable prognosis. Historically, systemic treatments for HCC have been scarce. In particular, sorafenib was the only registered drug for the treatment of unresectable HCC until 2017. Last year, regorafenib was approved by the global regulatory agencies as second-line therapy. Since then, further randomized, controlled trials have been successful in this patient population. This paper deals with the most recent data concerning cabozantinib and ramucirumab, the two drugs that have recently demonstrated efficacy in phase III, randomized, controlled trials in HCC patients who failed previous treatment with sorafenib.

Ielasi, L., Sansone, V., Granito, A., Benevento, F., De Lorenzo, S., Tovoli, F. (2018). An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib. DRUGS OF TODAY, 54(10), 615-627 [10.1358/dot.2018.54.10.2880176].

An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib

IELASI, LUCA;Sansone, V.;Granito, A.;Benevento, F.;De Lorenzo, S.;Tovoli, F.
2018

Abstract

Hepatocellular carcinoma (HCC) remains among the neoplastic diseases with the most unfavorable prognosis. Historically, systemic treatments for HCC have been scarce. In particular, sorafenib was the only registered drug for the treatment of unresectable HCC until 2017. Last year, regorafenib was approved by the global regulatory agencies as second-line therapy. Since then, further randomized, controlled trials have been successful in this patient population. This paper deals with the most recent data concerning cabozantinib and ramucirumab, the two drugs that have recently demonstrated efficacy in phase III, randomized, controlled trials in HCC patients who failed previous treatment with sorafenib.
2018
Ielasi, L., Sansone, V., Granito, A., Benevento, F., De Lorenzo, S., Tovoli, F. (2018). An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib. DRUGS OF TODAY, 54(10), 615-627 [10.1358/dot.2018.54.10.2880176].
Ielasi, L.; Sansone, V.; Granito, A.; Benevento, F.; De Lorenzo, S.; Tovoli, F.*
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/662737
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 9
social impact